

Document heading doi: 10.1016/S2305-0500(13)60154-2

Pharmacological and analytical aspects of withaferin A: A concise report of current scientific literature

Kanika Patel¹, Ravi B Singh², Dinesh K Patel^{3*}

¹G.L.A Institute of Pharmaceutical Research, Mathura, India

²Institute of Pharmacy, Harish Chandra Post Graduate College, Varanasi India

³Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi-221005, India

ARTICLE INFO

Article history:

Received 24 May 2013

Received in revised form 20 June 2013

Accepted 22 June 2013

Available online 20 September 2013

Keywords:

Analytical techniques

Cancer

Pharmacological activity

Withaferin A

Withania somnifera

ABSTRACT

Withaferin A is an important phytoconstituents of *Withania somnifera* (*W. Somnifera*) belonging to the category of withanolides, that are a group of naturally occurring C₂₈-steroidal lactone triterpenoids. Withaferin A has been used in the traditional and indigenous system of medicine for the treatment of various disorders. In view of its unique therapeutic potential, it has gained much attention in the modern science. In the couple of the years, Withaferin A has been scientifically validated for different pharmacological activities including anti-cancer, adaptogenic, anti-stress, anti-convulsant, immunomodulatory, neurological, anti-inflammatory, anti-tumor, cardioprotective, and neuroprotective activities. Pharmacological and analytical aspects of Withaferin A were highlighted in the present article. From the literature review it was found that Withaferin A has a very impressive pharmacological profile especially against cancer and could be useful for the development of the new drug in the future for the treatment of cancer and other metabolic disorders.

1. Introduction

Plants produce different kind of phytoconstituents during their development and in response to various environmental stimuli. Different enzymatic pathways produce secondary metabolites that alter by growth conditions such as climates, locations, microenvironments, etc. and different stresses (Physical and chemical stimuli). These changes cause a variation of the active phytochemicals present in the plant *i.e.* alkaloids, terpenoids, and phenylpropanoids etc. [1]. More than 12 alkaloids, 40 withanolides, and several sitoindosides have been isolated and reported from aerial parts, roots and berries of *Withania* species. Withaferin A was the first member of withanolide group to be isolated from the South-Asian medicinal plant, *Withania somnifera* (*W. Somnifera*). Lavie's [2]. Withanolides are groups of secondary metabolites that contain a steroid backbone attached with lactone or one of its derivatives. Withanolides

are mainly found in the Solanaceae group of plants such as *W. somnifera*. Withaferin A (Figure 1) is present in the roots and leaves of *W. somnifera* also known as Ashwagandha in Ayurvedic medicine and chemically classified in the steroidal compound (highly oxygenated C₂₈ steroid derivatives). Withaferin A can be easily extracted from roots and leaves of *W. somnifera* using different chromatographic techniques [3]. Use of withaferin A in the ancient times against various ailments has been reported in the literature. It showed antitumor, antiangiogenic and radiosensitizing activities. The anticancer activity of withaferin A have been investigated in prostate, breast and pancreatic cancers [4, 5]. Withaferin A is found to be a natural proteasome inhibitor, it induces actin microfilament aggregation and apoptosis by inhibiting Topoisomerase-IDNA complex. It acts as a mitotic poison (arrest tumor cells at metaphase), inhibits the umbilical vein endothelial cell sprouting, and promotes the formation of dendrites. Withaferin A showed antimetabolic properties, suppress adjuvant arthritis in rats, activate the peritoneal macrophages, increase the activity of lysosomal enzymes secreted by macrophages and exerts immunosuppressant activities. It also showed antimicrobial activities against both gram positive and gram negative bacteria [4].

*Corresponding author: Dinesh K. Patel, Department of Pharmaceutics, Indian Institute of Technology, Banaras Hindu University, Varanasi-221005, India.
Tel: +91 9919192440
E-mail: dkpatel.rs.phe@itbhu.ac.in




Figure 1. Chemical structure and overview of withaferin A.

2. Overview of withanolides

Withanolides are a group of naturally occurring C_{28} steroidal lactones characterized by the presence of an ergostan skeleton and frequently a delta lactone in C-17 [6, 7]. Withanolides are produced mainly by the Solanaceae family, in particular by the genera *Withania*, *Physalis*, *Datura*, *Nicandra*, *Dunalia*, *Lycium*, *Tubocapsicum* and *Jaborosa*. It has also been reported in Lamiaceae, Taccaceae and Fabaceae families and in some marine organisms. Withanolides display significant pharmacological activities including antimicrobial, antitumor, anti-inflammatory, hepatoprotective, immunomodulatory, antibacterial, insect-antifeedant, insect-repellent, antistress and immunosuppressive activities [6, 8]. Ecologically, the withanolides exhibit activity as feeding deterrents, as insecticides and ecdysteroid antagonists, and appear to be significant as a part of the chemical defense armamentarium of solanaceous plants [9].

3. Pharmacological significance of withaferin A

Withaferin A, a steroidal lactone purified from the Indian medicinal plant *W. somnifera* has attracted the attention of chemists as well as biologists due to its interesting structure and anti-cancer, adaptogenic, anti-stress, anti-convulsant, anti-inflammatory, cardioprotective, immunomodulatory and neurological effects. Withaferin A potently inhibits NF- κ B activation by preventing the TNF-induced activation of I κ B kinase β via a thioalkylation-sensitive redox mechanism. Withaferin A induces apoptosis through reactive oxygen species (ROS) generation, Par-4 induction and p38 MAP kinase activation [2, 10, 11]. Withaferin A exerts anticancer effect on prostate, colon, breast, leukemia, pancreatic, renal, head and neck cancer cells of human. It activates p38 MAP kinase, inhibits the Notch signalling pathway and nuclear factor- κ B activation, induces Akt inactivation, death receptor 5 (DR5) up-regulation and down-regulation of c-FLIP [12]. The anticancer activity of withaferin A has been demonstrated in prostate cancer cells, breast cancer cells, leukemia cells, and melanoma cells. Withaferin A induces apoptosis in prostate cancer cells through Par-4 induction, inhibits the chymotrypsin-like activity of proteasome, and targets the intermediate filament protein

vimentin by covalently modifying the cysteine residue. In addition, Withaferin A also targets Annexin II to induce Actin microfilament aggregation [13]. Anti-proliferative effect by G2/M phase cell cycle arrest, inhibition of cell adhesion molecules by inactivation of Akt and NF- κ B, and inhibition of colon cancer survival by down-regulating Notch, and induction of apoptosis by reactive oxygen species (ROS) generation has been reported for withaferin A. In addition, it also inhibits cell migration/invasion through down-regulation of STAT3 activity and induces apoptosis in human breast cancer cells [14].

Withaferin A alters cytoskeletal architecture by covalently binding annexin II, exerts antitumor activity by inhibiting proteasomal chymotrypsin-like activity, and induces apoptosis through the inhibition of protein kinase C [15]. Withaferin A triggered apoptosis through the modification of gene expression, mitochondrial depolarization, induction of oxidative stress or triggering of endoplasmic reticulum stress [16]. Withaferin A induced early reactive oxygen species (ROS) generation that caused the failure of nuclear factor- κ B (NF- κ B) binding to DNA as well as nuclear cleavage by activated caspase-3, leading to apoptosis. Withaferin A was also shown to suppress NF- κ B activation and its regulated genes' expression, including COX-2, intercellular adhesion molecule, inhibitor of apoptosis protein 1, and cellular FADD-like IL-1 β -converting enzyme inhibitory protein (c-FLIP), in cancer cells [17].

4. Pharmacological activities of withaferin A

The effect of withaferin A treatment on pancreatic islets cell viability was examined using the fluorescein diacetate-propidium iodide dye exclusion test and glucose stimulation assay. Withaferin A was found to be not toxic to the islet cells and inhibits the inflammatory response of islet cells to cytokine exposure [18]. The effects of withaferin A on MCF-7 viability and proliferation were evaluated by 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay and trypan blue exclusion assays. Withaferin A was found to show growth inhibition and decreased viability in MCF-7 cells [19]. Treatment of TDP-43(TAR DNA-binding protein 43) mice with withaferin A, an inhibitor of NF- κ B activity reduced denervation in the neuromuscular junction and disease symptoms [20]. In another study effect of withaferin A on Heat Shock Factor 1 (HSF1)-dependent stress response was evaluated and found to be active [21]. The effect of withaferin A on corneal angiogenesis and retinal gliosis was investigated. Withaferin A treatment potently inhibited corneal neovascularization and downregulated the expression of soluble and filamentous GFAP [22]. Effects of pure withaferin A on the isolated skin melanophores of frog was investigated. Withaferin A induced powerful dose-dependent physiologically significant melanin dispersal effects in the isolated skin melanophores, which were completely blocked by atropine and hyoscine [23]. Withaferin A inhibited lipopolysaccharide (LPS)-induced cyclooxygenase (COX)-2 mRNA and protein expression and prostaglandin E2 (PGE (2)) production in BV2 murine microglial cells. These results suggest that withaferin A inhibits LPS-induced PGE (2) production and COX-2 expression [24]. In computational analysis, the large value

of binding energy involved in binding of withaferin A to the active Hsp (Heat shock proteins) 90/Cdc37 complex consolidates the thermodynamic stability of the binding [25].

The effect of withaferin A in NF- κ B signalling pathway modulating capability was investigated and found that the trajectories of the native protein and the protein complexes with withaferin A are stable over a considerably long time period [26]. Proteasome inhibition capability of withaferin A was investigated and found that withaferin A can inhibit the mammalian proteasomes irreversibly and with a high rate through acylation of the N-terminal Thr1 of the β -5 subunit [27]. The effect of withaferin A on inhibition of Hsp90/Cdc37 chaperone/co-chaperone association complex was investigated. Molecular docking studies reveal that withaferin A in combination with 17-DMAG can act as potent chaperone system inhibitors [28]. In another study it was found that withaferin A markedly inhibit *Escherichia coli* induced polymorphonuclear neutrophil (PMN) transmigration, a dual inhibitor of vimentin and proteasome [29]. Gliosis is a biological process that occurs during injury repair in the central nervous system and is characterized by the overexpression of the intermediate filaments glial fibrillary acidic protein and vimentin. Withaferin A is a novel chemical probe of glial fibrillary acidic protein [30]. Oral administration of withaferin A to 7,12-dimethylbenz(a)anthracene (DMBA)-treated animals significantly reduced the formation of tumors and synchronized the status of lipid peroxidation and antioxidants potential [31]. Growth inhibition and differentiation potential of the withaferin A, on glioma (C6 and YKG1) cell lines was investigated and found that withaferin A markedly inhibited the proliferation of glioma cells in a dose-dependent manner [32]. The effect of withaferin A in *in vitro* model of CF-related inflammation was also investigated [33]. Cotreatment with subtoxic doses of withaferin A and tumor necrosis factor-related apoptosis-inducing ligand was investigated and found that withaferin A induces apoptosis in human renal cancer cells and Caki cells [17].

The role of withaferin A on airway inflammation and its mechanism was investigated and found that withaferin A inhibit the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in human lung epithelial A549 cells [10]. The effect of withaferin A on the development and decay of thermotolerance in B16F1 melanoma was studied in C57BL mice. Withaferin A increases the tumor response during repeated hyperthermia by reducing the magnitude of thermotolerance developed and by decreasing the recovery time from thermotolerance [34]. The effect of withaferin A on monosodium urate crystal-induced inflammation in mice was investigated. Paw volume, the levels of lysosomal enzymes, lipid peroxidation, and inflammatory mediator tumour necrosis factor- α were found to be reversed in the withaferin A treated group as compared to control group [35]. Withaferin A induces apoptosis in association with the activation of caspase-3. Results indicated that the JNK and Akt pathways and inhibition of NF- κ B activity were key regulators of apoptosis in response to withaferin A in human leukemia U937 cells [36]. Withaferin A caused increased levels of Bax in response to MAPK signaling, which resulted in the initiation of a mitochondrial death cascade. It can be used as new, alternative, inexpensive chemotherapeutic agent

for the treatment of leukemia of both lymphoid and myeloid origin [37]. Administration of withaferin A with human filarial parasite *Brugia malayi*, offers differential protection in *Mastomys coucha* with chemotype 101R offering better protection as compared to other chemotypes [38].

The effect of withaferin A in inhibiting viral DNA polymerase was investigated and found to bind very similarly to that of the previously reported 4-oxo-DHQ inhibitor [39]. The effects of withaferin A was examined in CaOV3 and SKOV3 ovarian carcinoma cell lines using the MTS assay, clonogenic assay, annexin V/propidium iodide flow cytometry and cell cycle analysis. Withaferin A inhibits CaOV3 and SKOV3 ovarian carcinoma cell growth [40]. Withaferin A was evaluated for antitumor activity in pancreatic cancer cells with confirmatory RT-PCR and Western blotting assay. Withaferin A analog showed dose and time dependent apoptosis and inhibits proliferation [41]. Withaferin A enhances the ionizing radiation (IR)-induced apoptosis in human lymphoma U937 cells which is associated with the PARP cleavage, caspase-3 activation, as well as specifically down-regulation of anti-apoptotic protein Bcl-2 [30]. Effects of withaferin A on human cervical cancer cells *in vitro* and *in vivo* were investigated. Withaferin A potently inhibited proliferation of the cervical cancer cells, and was found to downregulate expression of HPV E6 and E7 oncoproteins [4]. Withaferin A-induced apoptosis is mediated by reactive oxygen species (ROS) production which is mainly due to inhibition of mitochondrial respiration [43]. Imaging of breast cancer cell lines revealed that withaferin A induces perinuclear vimentin accumulation followed by rapid vimentin depolymerization revealed its potent breast cancer anti-metastatic agent [44]. Withaferin A, an anti-estrogen and the proapoptotic effect is partially attenuated by p53 knockdown and E2-ER- α [45]. Withaferin A induced a dose-dependent apoptotic cell death in several types of human cancer cells, as measured by FACS analysis and PARP cleavage [46]. The effect of Withaferin A on radiation-induced apoptosis in human renal cancer cells (Caki cells) were investigated and found that compared with withaferin A or radiation alone, the combination of both resulted in a significant enhancement of apoptosis [14]. Fifteen gene-targets were identified and were investigated for their role in specific cancer cell killing activity of withaferin A by undertaking the shRNA-mediated gene silencing approach [47].

The anticancer potential of withaferin A tested against the head and neck squamous cell carcinoma (HNSCC) cell lines, MDA1986, JMAR, UM-SCC-2, and JHU011 and found that it had antiproliferative activity against head and neck squamous carcinoma [48]. Withaferin A inhibits constitutive as well as interleukin-6 (IL-6)-inducible activation of signal transducer and activator of transcription 3 (STAT3), which is an oncogenic transcription factor activated in many human malignancies including breast cancer [49]. The tumor sensitizing effect of withaferin A with or without local hyperthermia on the response of B16F1 melanoma to fractionated and acute radiotherapy was investigated. Withaferin A is a better radiosensitizer than HT in fractionated regimen and the response of radioresistant tumors like melanoma [50]. Withaferin-A elicited marked apoptosis and vimentin cleavage in vimentin-expressing tumor cells but significantly less in normal mesenchymal cells. Moreover, withaferin-A significantly blocked soft tissue sarcoma

growth, local recurrence, and metastasis in a panel of soft tissue sarcoma xenograft experiments [51]. Withaferin A is a bioactive compound which inhibits Notch-1 signaling and downregulates pro-survival pathways, such as Akt/NF- κ B/Bcl-2 in three colon cancer cell lines (HCT-116, SW-480, and SW-620) [5]. Efficacy and the mechanism of Hsp90 inhibition of withaferin A in pancreatic cancer *in vitro* and *in vivo* were investigated. Withaferin A binds Hsp90, inhibits Hsp90 chaperone activity through an ATP-independent mechanism [13]. Withaferin A was found to repress IL-6 gene transcription in metastatic breast cancer cells upon dual inhibition of NF- κ B and AP-1 Fra-1 transcription factors and silencing of IL-6 promoter chromatin accessibility [52]. The protective effect of withaferin-A in 7,12-dimethylbenz[a]anthracene (DMBA) induced oral carcinogenesis in Syrian golden hamsters was investigated. Oral administration of withaferin-A for 14 weeks completely prevented the tumour incidence, tumour volume and tumour burden [53]. The protective effect of withaferin-A on molecular pathogenesis of oral cancer by evaluating the immunoeexpression of p53 and bcl-2 proteins were investigated. Withaferin-A has significant protective role against 7,12-dimethylbenz(a)anthracene (DMBA) induced molecular alterations in the buccal mucosa of golden Syrian hamsters [54]. Withaferin A treatment causes G2 and mitotic arrest in human breast cancer cells [55].

5. Analytical aspects of withaferin A

Withaferin A was isolated from *W. somnifera* (Solanaceae). All structures were elucidated on the basis of spectroscopic methods (IR, HRESIMS, 1D/2D NMR) and X-ray crystallography [56]. A rapid and sensitive high-performance liquid chromatography method for determination of withaferin A in human plasma was developed using reverse-phase C₁₈ column, water and acetonitrile as a mobile phase with UV-visible detection at 225 nm [57]. Withaferin A was isolated from *Ajuga bracteosa* Wall using ethanolic extract by silica gel column chromatography [58]. Metabolic characterization of *W. somnifera* leaves, stems, and roots collected in six different regions in India was performed using ¹H NMR spectroscopy followed by principal component analysis and hierarchical clustering analysis using withaferin A as a marker compound [59]. Phytochemical studies on the aerial parts of *W. somnifera* L. Dunal. led to the isolation of withaferin A with some other compounds [60]. In another study, withaferin A was extracted using a microwave-assisted extraction technique from the air-dried aerial part of *W. somnifera* Duna [61].

The hydroalcoholic fraction of *Withania coagulans* Dunal was standardized by withaferin A using high performance thin layer chromatography [62]. In another study *W. somnifera* extract was analyzed by liquid chromatography–serial mass spectrometry and found to be present numerous withanolide derivatives including withaferin A [63]. Modified and validated HPLC–DAD method for quantitative measurement of withanolides including withaferin A and fingerprint analysis was developed and validated [64]. Reverse-phase preparative HPLC analysis of the n-butanol fraction of *W. somnifera* showed the presence of a novel chlorinated withanolide namely withanolide Z and withaferin A [65].

A sensitive, selective, specific, robust, and validated densitometric high-performance thin-layer chromatographic method for the simultaneous determination of withaferin A in *W. somnifera* using dichloromethane–methanol–acetone–diethyl ether as the mobile phase was developed [66].

6. Conclusion

Medicinal plants were used for the treatment of different type of diseases in several ways in the very early age [67]. The plant contains different type of phytoconstituents which showed different pharmacological activities. Treatment of various health ailments by plant material has been in practice from time immemorial [68]. More than 80% of the World's population in 2001 used herbal medicine for their primary health care [69]. Before the development of the synthetic drug natural products were used as alternative therapy for the treatment of various diseases [70, 71]. Herbal medicines are used for treatment of various ailments in the world due to the belief of its fewer side effects. Many synthetic and natural compounds have been obtained from different natural sources such as plants, minerals and organic matter. Natural materials are an emerging field of food science because of their increasing popularity with consumers concerned about health. To maintain proper growth, the pharmaceutical industries need to innovate and access to high output rate on low-cost materials with reasonable safety. The combination of modern chemistry with bio-based starting materials can be the scope of revolutionizing pharmaceutical industries. Withaferin A is found in many plants and have an important place in the different system of medicine due to its unique property and pharmacological activities. Many investigations have been carried out to explore the hidden potential of withaferin A and result showed that it has significant anticancer and other pharmacological activities. The information presented in this review will be helpful to the researcher to explore the hidden potential of withaferin A.

Declare of interest statement

The authors report no conflict of interest.

References

- [1] Xu YM, Gao S, Bunting DP, Gunatilaka AA. Unusual withanolides from aeroponically grown *Withania somnifera*. *Phytochemistry* 2011; **72**: 518–522.
- [2] Yousuf SK, Majeed R, Ahmad M, Sangwan PI, Purnima B, Saxsena AK, et al. Ring A structural modified derivatives of withaferin A and the evaluation of their cytotoxic potential. *Steroids* 2011; **76**: 1213–1222.
- [3] Pavithra K, Priyadarshini B. Versatile antiangiogenic steroid – withaferin A. *Advan Biotech* 2008; **1**: 27–28.
- [4] Munagala R, Kausar H, Munja C, Gupta RC. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. *Carcinogenesis* 2011; **32**: 1697–1705.
- [5] Koduru S, Kumar R, Srinivasan S, Evers MB, Damodaran C.

- Notch-1 Inhibition by withaferin-A: A therapeutic target against colon carcinogenesis. *Mol Cancer Ther* 2010; **9**: 202–210.
- [6] Fang ST, Liu JK, Li B. Ten new withanolides from *Physalis peruviana*. *Steroids* 2012; **77**: 36–44.
- [7] Cordero CP, Morantes SJ, Páez A, Rincón J, Aristizábal FA. Cytotoxicity of withanolides isolated from *Acnistus arborescens*. *Fitoterapia* 2009; **80**(6): 364–368
- [8] Lan YH, Chang FR, Pan MJ, Wu CC, Wu SJ, Chen SL, et al. New cytotoxic withanolides from *Physalis peruviana*. *Food Chem* 2009; **116**: 462–469.
- [9] Minguzzi S, Barata LE, Shin YG, Jonas PF, Chai HB, Park EJ, et al. Cytotoxic withanolides from *Acnistus rboescens*. *Phytochemistry* 2002; **59**: 635–641.
- [10] Oh JH, Kwon TK. Withaferin A inhibits tumor necrosis factor- α -induced expression of cell adhesion molecules by inactivation of Akt and NF- κ B in human pulmonary epithelial cells. *Int Immunopharmacol* 2009; **9**: 614–619.
- [11] Um HJ, Min KJ, Kim DE, Kwon TK. Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells. *Biochem Biophys Res Commun* 2012; **427**: 24–29.
- [12] Llanos GG, Araujo LM, Jiménez IA, Moujir LM, Bazzocchi IL. Withaferin A-related steroids from *Withania aristata* exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells. *Eur J Med Chem* 2012; **54**: 499–511.
- [13] Yu Y, Hamza A, Zhang T, Gu M, Zou P, Newman B, et al. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. *Biochem Pharmacol* 2010; **79**: 542–551.
- [14] Yang ES, Choi MJ, Kim JH, Choi KS, Kwon TK. Withaferin A enhances radiation-induced apoptosis in Caki cells through induction of reactive oxygen species, Bcl-2 downregulation and Akt inhibition. *Chem Biol Interact* 2011; **190**: 9–15.
- [15] Oh JH, Lee TJ, Park JW, Kwon TK. Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF- κ B in RAW 264.7 cells. *Eur J Pharmacol* 2008; **599**: 11–17.
- [16] Jilani K, Lupescu A, Zbidah M, Shaik N, Lang F. Withaferin A-stimulated Ca²⁺ entry, ceramide formation and suicidal death of erythrocytes. *Toxicol In Vitro* 2013; **27**: 52–58.
- [17] Lee TJ, Um HJ, Min do S, Park JW, Choi KS, Kwon TK. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. *Free Radic Biol Med* 2009; **46**: 1639–1649.
- [18] Peng H, Olsen G, Tamura Y, Noguchi H, Matsumoto S, Levy MF, et al. Inhibition of inflammatory cytokine-induced response in human islet cells by withaferin A. *Transplant Proc* 2010; **42**: 2058–2061.
- [19] Zhang X, Mukerji R, Samadi AK, Cohen MS. Down-regulation of estrogen receptor- α and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells. *BMC Complement Altern Med* 2011; **6**(11): 84.
- [20] Swarup V, Phaneuf D, Dupré N, Petri S, Strong M, Kriz J, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor κ B-mediated pathogenic pathways. *J Exp Med* 2011; **208**: 2429–2447.
- [21] Santagata S, Xu YM, Wijeratne EM, Kontnik R, Rooney C, Perley CC, et al. Using the heat-shock response to discover anticancer compounds that target protein homeostasis. *ACS Chem Biol* 2012; **7**: 340–349.
- [22] Paranthan RR, Bargagna-Mohan P, Lau DL, Mohan R. A robust model for simultaneously inducing corneal neovascularization and retinal gliosis in the mouse eye. *Mol Vis* 2011; **17**: 1901–1908.
- [23] Ali SA, Meitei KV. On the action and mechanism of withaferin-A from *Withania somnifera*, a novel and potent melanin dispersing agent in frog melanophores. *J Recept Signal Transduct Res* 2011; **31**: 359–366.
- [24] Min KJ, Choi K, Kwon TK. Withaferin A down-regulates lipopolysaccharide-induced cyclooxygenase-2 expression and PGE2 production through the inhibition of STAT1/3 activation in microglial cells. *Int Immunopharmacol* 2011; **11**: 1137–1142.
- [25] Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, Bisaria VS, et al. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. *BMC Bioinformatics* 2011; **12**: S30.
- [26] Grover A, Shandilya A, Punetha A, Bisaria VS, Sundar D. Inhibition of the NEMO/IKK β association complex formation, a novel mechanism associated with the NF- κ B activation suppression by Withania somnifera's key metabolite withaferin A. *BMC Genomics* 2010; **11**: S25.
- [27] Grover A, Shandilya A, Bisaria VS, Sundar D. Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes. *BMC Genomics* 2010; **11**: S15.
- [28] Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, Bisaria VS, et al. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors. *Biochem Biophys Res Commun* 2011; **404**: 498–503.
- [29] Che X, Chi F, Wang L, Jong TD, Wu CH, Wang X, et al. Involvement of IbeA in meningitic *Escherichia coli* K1-induced polymorphonuclear leukocyte transmigration across brain endothelial cells. *Brain Pathol* 2011; **21**: 389–404.
- [30] Bargagna-Mohan P, Paranthan RR, Hamza A, Dimova N, Trucchi B, Srinivasan C, et al. Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosis. *J Biol Chem* 2010; **285**: 7657–7669.
- [31] Manoharan S, Panjamurthy K, Balakrishnan S, Vasudevan K, Vellaichamy L. Circadian time-dependent chemopreventive potential of withaferin-A in 7,12-dimethylbenz[a]anthracene-induced oral carcinogenesis. *Pharmacol Rep* 2009; **61**: 719–726.
- [32] Shah N, Kataria H, Kaul SC, Ishii T, Kaur G, Wadhwa R. Effect of the alcoholic extract of Ashwagandha leaves and its components on proliferation, migration, and differentiation of glioblastoma cells: combinational approach for enhanced differentiation. *Cancer Sci* 2009; **100**: 1740–1747.
- [33] Maitra R, Porter MA, Huang S, Gilmour BP. Inhibition of NF κ B by the natural product Withaferin A in cellular models of cystic fibrosis inflammation. *J Inflamm* 2009; **6**: 15.
- [34] Kalthur G, Mutalik S, Pathirissery UD. Effect of withaferin A on the development and decay of thermotolerance in B16F1 melanoma: a preliminary study. *Integr Cancer Ther* 2009; **8**: 93–97.
- [35] Sabina EP, Chandal S, Rasool MK. Inhibition of monosodium urate crystal-induced inflammation by withaferin A. *J Pharm Pharm Sci* 2008; **11**: 46–55.
- [36] Oh JH, Lee TJ, Kim SH, Choi YH, Lee SH, Lee JM, et al. Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. *Apoptosis* 2008; **13**: 1494–1504.
- [37] Mandal C, Dutta A, Mallick A, Chandra S, Misra L, Sangwan RS, et al. Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. *Apoptosis* 2008; **13**: 1450–1464.
- [38] Kushwaha S, Soni VK, Singh PK, Bano N, Kumar A, Sangwan RS,

- et al. Withania somnifera chemotypes NMITLI 101R, NMITLI 118R, NMITLI 128R and withaferin A protect *Mastomys coucha* from *Brugia malayi* infection. *Parasite Immunol* 2012; **34**: 199–209.
- [39] Grover A, Agrawal V, Shandilya A, Bisaria VS, Sundar D. Non-nucleosidic inhibition of herpes simplex virus DNA polymerase: mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin A. *BMC Bioinformatics* 2011; **13**: S22.
- [40] Zhang X, Samadi AK, Roby KF, Timmermann B, Cohen MS. Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide withaferin A. *Gynecol Oncol* 2012; **124**: 606–612.
- [41] Liu X, Qi W, Cooke LS, Kithsiri Wijeratne EM, Xu YM, Marron MT, et al. An analog of withaferin A activates the MAPK and glutathione “stress” pathways and inhibits pancreatic cancer cell proliferation. *Cancer Invest* 2011; **29**: 668–675.
- [42] Yang ES, Choi MJ, Kim JH, Choi KS, Kwon TK. Combination of withaferin A and X-ray irradiation enhances apoptosis in U937 cells. *Toxicol In Vitro* 2011; **25**: 1803–1810
- [43] Hahm ER, Moura MB, Kelley EE, Van Houten B, Shiva S, Singh SV. Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. *PLoS One* 2011; **6**: e23354.
- [44] Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, et al. Withaferin a suppresses estrogen receptor- α expression in human breast cancer cells. *Mol Carcinog* 2011; **50**: 614–624.
- [45] Hahm ER, Lee J, Huang Y, Singh SV. Withaferin a suppresses estrogen receptor- α expression in human breast cancer cells. *Mol Carcinog* 2011; **50**(8): 614–624.
- [46] Choi MJ, Park EJ, Min KJ, Park JW, Kwon TK. Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells. *Toxicol In Vitro* 2011; **25**: 692–698.
- [47] Widodo N, Priyandoko D, Shah N, Wadhwa R, Kaul SC. Selective killing of cancer cells by Ashwagandha leaf extract and its component withanone involves ROS signaling. *PLoS One* 2010; **5**: e13536.
- [48] Samadi AK, Tong X, Mukerji R, Zhang H, Timmermann BN, Cohen MS. Withaferin A, a cytotoxic steroid from *Vassobia breviflora*, induces apoptosis in human head and neck squamous cell carcinoma. *J Nat Prod* 2010; **73**: 1476–1481.
- [49] Lee J, Hahm ER, Singh SV. Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. *Carcinogenesis* 2010; **31**: 1991–1998.
- [50] Kalthur G, Pathirissery UD. Enhancement of the response of B16F1 melanoma to fractionated radiotherapy and prolongation of survival by withaferin A and/or hyperthermia. *Integr Cancer Ther* 2010; **9**: 370–377.
- [51] Lahat G, Zhu QS, Huang KL, Wang S, Bolshakov S, Liu J, et al. Vimentin is a novel anti-cancer therapeutic target; insights from *in vitro* and *in vivo* mice xenograft studies. *PLoS One* 2010; **5**: e10105.
- [52] Ndlovu MN, Van Lint C, Van Wesemael K, Callebert P, Chalbos D, Haegeman G, et al. Hyperactivated NF- κ B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. *Mol Cell Biol* 2009; **29**: 5488–5504.
- [53] Manoharan S, Panjamurthy K, Menon VP, Balakrishnan S, Alias LM. Protective effect of Withaferin-A on tumour formation in 7,12-dimethylbenz[a]anthracene induced oral carcinogenesis in hamsters. *Indian J Exp Biol* 2009; **47**: 16–23.
- [54] Panjamurthy K, Manoharan S, Nirmal MR, Vellaichamy L. Protective role of Withaferin-A on immunoexpression of p53 and bcl-2 in 7,12-dimethylbenz(a)anthracene-induced experimental oral carcinogenesis. *Invest New Drugs* 2009; **27**: 447–452.
- [55] Stan SD, Zeng Y, Singh SV. Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. *Nutr Cancer* 2008; **60**: 51–60.
- [56] Tong X, Zhang H, Timmermann BN. Chlorinated withanolides from *Withania somnifera*. *Phytochem Lett* 2011; **4**: 411–414.
- [57] Patial P, Gota V. Rapid and sensitive method for determination of withaferin-A in human plasma by HPLC. *Bioanalysis* 2011; **3**: 285–289.
- [58] Gautam R, Jachak SM, Saklani A. Anti-inflammatory effect of *Ajuga bracteosa* Wall Ex Benth. mediated through cyclooxygenase (COX) inhibition. *J Ethnopharmacol* 2011; **133**: 928–930.
- [59] Namdeo AG, Sharma A, Yadav KN, Gawande R, Mahadik KR, Lopez-Gresa MP, et al. Metabolic characterization of *Withania somnifera* from different regions of India using NMR spectroscopy. *Planta Med* 2011; **77**: 1958–1964.
- [60] Choudhary MI, Hussain S, Yousuf S, Dar A, Mudassar, Atta-ur-Rahman. Chlorinated and diepoxy withanolides from *Withania somnifera* and their cytotoxic effects against human lung cancer cell line. *Phytochemistry* 2010; **71**: 2205–2209.
- [61] Mirzajani F, Ghassempour A, Jalali-Heravi M, Mirjalili MH. Optimisation of a microwave-assisted method for extracting withaferin A from *Withania somnifera* Dunal. using central composite design. *Phytochem Anal* 2010; **21**: 544–549.
- [62] Prasad SK, Kumar R, Patel DK, Hemalatha S. Wound healing activity of *Withania coagulans* in streptozotocin-induced diabetic rats. *Pharm Biol* 2010; **48**: 1397–1404.
- [63] Kumar S, Seal CJ, Howes MJ, Kite GC, Okello EJ. *In vitro* protective effects of *Withania somnifera* (L.) dunal root extract against hydrogen peroxide and β -amyloid(1–42)-induced cytotoxicity in differentiated PC12 cells. *Phytother Res* 2010; **24**: 1567–1574.
- [64] Patil D, Gautam M, Jadhav U, Mishra S, Karupothula S, Gairola S, et al. Physicochemical stability and biological activity of *Withania somnifera* extract under real-time and accelerated storage conditions. *Planta Med* 2010; **76**: 481–488.
- [65] Pramanick S, Roy A, Ghosh S, Majumder HK, Mukhopadhyay S. Withanolide Z. a new chlorinated withanolide from *Withania somnifera*. *Planta Med* 2008; **74**: 1745–1748.
- [66] Srivastava P, Tiwari N, Yadav AK, Kumar V, Shanker K, Verma RK, et al. Simultaneous quantification of withanolides in *Withania somnifera* by a validated high-performance thin-layer chromatographic method. *JAOAC Int* 2008; **91**: 1154–1161.
- [67] Patel DK, Kumar R, Prasad SK, Hemalatha S. Pharmacologically screened aphrodisiac plant—A review of current scientific literature. *Asian Pac J Trop Biomed* 2011; **1**: S131–S138.
- [68] Patel DK, Laloo D, Kumar R, Hemalatha S. *Pedaliium murex* Linn—An overview of its phytopharmacological aspects. *Asian Pac J Trop Med* 2011; **4**: 748–755.
- [69] Patel DK, Prasad SK, Kumar R, Hemalatha S. Cataract: A major secondary complication of diabetes, its epidemiology and an overview on major medicinal plants screened for anticataract activity. *Asian Pac J Trop Dis* 2011; **1**: 323–329.
- [70] Patel DK, Prasad SK, Kumar R, Hemalatha S. An overview on anti-diabetic medicinal plants having insulin mimetics property. *Asian Pac J Trop Biomed* 2012; **2**: 320–330.
- [71] Patel DK, Kumar R, Laloo D, Hemalatha S. Diabetes mellitus: An overview on its pharmacological aspects and reported medicinal plants having anti-diabetic activity. *Asian Pac J Trop Biomed* 2012; **2**: 411–420